Anita Afzali

Statistics

Publications

Citations

H-Index

Active since

2024

Affiliations

Johnson & Johnson (Switzerland)(Current)

Anita Afzali is an author at Johnson & Johnson (Switzerland) specializing in inflammatory bowel disease pathophysiology, medicine, and crohn disease pharmacotherapy.

Publications per year

2024–2025

Publications

Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials

Remo Panaccione, Brian G. Feagan, Anita Afzali et al. · The Lancet · 2025 · 37 citations · Full text

Pharmacy, Clinical Sciences, Pharmacotherapy +11

EFFICACY AND SAFETY OF GUSELKUMAB THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS OF THE GALAXI 2 & 3 PHASE 3 STUDIES

Remo Panaccione, Silvio Danese, Brian G. Feagan et al. · Gastroenterology · 2024 · 28 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +8

1–2 of 2